The impact of the COVID-19 pandemic on antimicrobial usage: An international patient-level cohort study
Farzana R., Harbarth SJ., Yu LM., Carretto E., Moore CE., Feasey NA., Gales AC., Galal U., Ergonul O., Yong D., Yusuf MA., Veeraraghavan B., Iregbu KC., Van Santen JA., Ribeiro ACDS., Fankhauser CM., Chilupsya CJ., Dolecek C., Ferreira DB., Pinarlik F., Jang J., Gücer LS., Cavazzuti L., Sultana M., Nazmul Haque MD., Haddad MG., Medugu N., Nwajiobi-Princewill PI., Marrollo R., Zhao R., Baskaran VB., Peter JV., Chandy SJ., Bakthavatchalam YD., Walsh TR., Paulina K., Prabaa D., Ragupathi NKD., Azap A., Gülten E., Ates E., Azap Ö., Sari N., Karaoglan I., Koçak K., Mete Ö., Coskun E., Kutlu M., Aksakal SÖ., Aydin M., Özer MÇ., Menekse S., Karahan ZC., Erdin BN., Abdessalam C., Colaizzi N., Fonton P., Stucki C., Bianchi R., Bruni L., Capatti C., Kassem S., Navazio F., Paolucci M., Roatti B., Abdulraheem K., Akujobi T., Falodun O., Fibresima F., Abir AA., Arefin S., Deb M., Disha PI., Eva FA., Hasan KR., Islam A., Islam HS., Jannat KT., Liya ZS., Nadia FA., Prova AA., Rahman S., Rafiqul Islam SM., Sabbir A., Talukder S., Tuly SJ., Jones L., Wootton M.
Background: This study aimed to evaluate the trends in antimicrobial prescription during the first 1.5 years of COVID-19 pandemic. Methods: This was an observational, retrospective cohort study using patient-level data from Bangladesh, Brazil, India, Italy, Malawi, Nigeria, South Korea, Switzerland and Turkey from patients with pneumonia and/or acute respiratory distress syndrome and/or sepsis, regardless of COVID-19 positivity, who were admitted to critical care units or COVID-19 specialized wards. The changes of antimicrobial prescription between pre-pandemic and pandemic were estimated using logistic or linear regression. Pandemic effects on month-wise antimicrobial usage were evaluated using interrupted time series analyses (ITSAs). Results: Antimicrobials for which prescriptions significantly increased during the pandemic were as follows: meropenem in Bangladesh (95% CI: 1.94-4.07) with increased prescribed daily dose (PDD) (95% CI: 1.17-1.58) and Turkey (95% CI: 1.09-1.58), moxifloxacin in Bangladesh (95% CI: 4.11-11.87) with increased days of therapy (DOT) (95% CI: 1.14-2.56), piperacillin/tazobactam in Italy (95% CI: 1.07-1.48) with increased DOT (95% CI: 1.01-1.25) and PDD (95% CI: 1.05-1.21) and azithromycin in Bangladesh (95% CI: 3.36-21.77) and Brazil (95% CI: 2.33-8.42). ITSA showed a significant drop in azithromycin usage in India (95% CI: -8.38 to -3.49â€...g/100 patients) and South Korea (95% CI: -2.83 to -1.89 g/100 patients) after WHO guidelines v1 release and increased meropenem usage (95% CI: 93.40-126.48 g/100 patients) and moxifloxacin (95% CI: 5.40-13.98 g/100 patients) in Bangladesh and sulfamethoxazole/trimethoprim in India (95% CI: 0.92-9.32 g/100 patients) following the Delta variant emergence. Conclusions: This study reinforces the importance of developing antimicrobial stewardship in the clinical settings during inter-pandemic periods.